Yong'an Pharmaceutical, long regarded as a leading domestic producer of taurine, has told investors to expect a steep earnings decline in 2025 as the commodity that underpins a slice of China’s beverage and pet-food industries weakens. The company forecasted net profit attributable to shareholders of RMB 18.19 million to RMB 27.05 million for 2025, a slump of roughly 56–71% from RMB 61.77 million a year earlier, citing falling sales volumes and lower selling prices for taurine.
Taurine straddles several markets: it is both a chemical intermediate and a nutritional additive used heavily in functional drinks and pet food, especially cat food. China supplies the lion’s share of the world’s taurine, with only modest output in Japan outside of the mainland. Yong'an’s annual production capacity reached about 78,000 tonnes during the reporting period, yet industrywide headwinds — volatile upstream raw-material costs, weaker downstream demand and intensified competition — have driven a marked price decline. Market-data cited by the company show a fall from about RMB 24,300/ton in 2023 to RMB 17,000/ton in 2024 and roughly RMB 14,700/ton in 2025; a February 2026 estimate put the price near RMB 17,200/ton but on a downward trajectory.
In response, Yong'an is redirecting resources to its downstream and value-added operations. On March 2, 2026 the firm announced a planned RMB 50 million capital injection into its wholly owned subsidiary Yong'an Kangjian (Wuhan), boosting the subsidiary’s registered capital from RMB 110 million to RMB 160 million. Management argues the cash will strengthen new product lines, complete business layouts and shore up daily operations. Yong'an Kangjian's own revenue has been growing fast: the unit reported RMB 57.42 million for the first half of 2025, up 76% year-on-year, and unaudited revenue of about RMB 101 million through the third quarter — already ahead of full-year 2024 revenue of RMB 75 million.
That growth, however, is concentrated in contract-manufacturing rather than in branded sales. Contract production accounted for roughly RMB 51.84 million of Yong'an Kangjian’s mid-2025 revenue, while its own-brand business contributed about RMB 5.56 million, highlighting how the firm currently relies on tolling and OEM margins while it builds brand recognition.
Investor confidence faces additional strain from governance and disclosure issues. In January 2026 Hubei securities regulators issued a warning to Yong'an after the company failed to meet certain mandatory disclosure and trading-stop obligations when shareholdings were reduced by a controlling shareholder and related parties. The regulator cited a failure to suspend share sales and to issue timely reports when holdings crossed a 5% integer threshold; the infractions involved a small, but regulatory-significant, sale of 83,400 shares. Senior executives have also continued modest share sales in early 2026.
For international commodity-watchers and downstream buyers, the immediate implication is simple: cheaper taurine input costs for beverage makers and pet-food producers, but thinner margins and potential consolidation among Chinese producers. For investors, the combination of a cyclical commodity downturn and governance blemishes makes Yong'an a case study in how commodity-led manufacturers must pivot to higher-margin operations and stricter corporate discipline to preserve valuation.